Evidence map›Paper›PMID 31656019›Full record

ArticlePathology oncology research : POR2020

Renal Cell Carcinoma with Clear Cell Papillary Features: Perspectives of a Differential Diagnosis.

Áron Somorácz, Levente Kuthi, Tamás Micsik, Alex Jenei, Adrienn Hajdu, Brigitta Vrabély, Erzsébet Rásó, Zoltán Sápi, Zoltán Bajory, Janina Kulka and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Renal Cell Carcinoma in End-Stage Renal Disease: A Retrospective Study in Patients from Hungary.Pathobiology : journal of immunopathology, molecular and cellular biology · 2023
    Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Áron Somorácz2nd Department of Pathology, Semmelweis University, Üllői út 93, Budapest, H-1091, Hungary. somoracz14@gmail.com.ORCID http://orcid.org/0000-0003-0227-5529
Levente KuthiDepartment of Pathology, University of Szeged, Szeged, Hungary.
Tamás Micsik1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Alex JeneiDepartment of Pathology, University of Szeged, Szeged, Hungary.
Adrienn HajduDepartment of Pathology, University of Szeged, Szeged, Hungary.
Brigitta Vrabély1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Erzsébet Rásó2nd Department of Pathology, Semmelweis University, Üllői út 93, Budapest, H-1091, Hungary.
Zoltán Sápi1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Zoltán BajoryDepartment of Urology, University of Szeged, Szeged, Hungary.
Janina Kulka2nd Department of Pathology, Semmelweis University, Üllői út 93, Budapest, H-1091, Hungary.
Béla IványiDepartment of Pathology, University of Szeged, Szeged, Hungary.
Semmelweis University · HUUniversity of Szeged · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thirty-one cases of low-grade renal cell carcinoma (RCC) with clear cells and tubulopapillary/papillary architecture were analyzed retrospectively with immunohistochemical and genetic markers to gain more experience with the differential diagnosis of such cases. All samples coexpressed CK7 and CA9; the TFE3 or TFEB reactions were negative; the CD10 and the AMACR stainings were negative in 27 cases and 30 cases, respectively. The FISH assays for papillary RCC, available in 27 cases, and deletion of chromosome 3p, available in 29 cases, gave negative results. The results for 3p deletion, VHL gene mutation or VHL gene promoter region hypermethylation testing, along with the diffuse CD10-positivity in 2 cases confirmed 21 cases as clear cell papillary RCC (CCPRCC; CK7+, CA9+; no 3p loss, no VHL abnormality) and 10 cases as clear cell RCC (CCRCC; CK7+, CA9+; no 3p loss, VHL abnormality mutation/hypermethylation present). In CCPRCCs, the representative growth pattern was branching tubulo-acinar, commonly accompanied by cyst formation. The linear nuclear arrangement or cup-shaped staining of CA9 did not necessarily indicate CCPRCC, and the absence of these did not exclude the diagnosis of CCPPRC. One tumor infiltrated the renal sinus; the others exhibited pT1 stage; and metastatic outcome was not recorded. The CCRCC cases were in pT1 stage; 6 exhibited cup-shaped staining of CA9, and 1 displayed lymph node metastasis at the time of surgery. Distant metastatic disease was not observed. In summary, the VHL abnormalities distinguished the subset of CCRCC with diffuse CK7-positivity and no 3p loss from cases of CCPRCC.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, PapillaryCarcinoma, Renal CellDiagnosis, DifferentialDNA MethylationFemaleHumansKidney NeoplasmsMaleMiddle AgedRetrospective StudiesVon Hippel-Lindau Tumor Suppressor ProteinBiomarkers, TumorVHL protein, humanVon Hippel-Lindau Tumor Suppressor ProteinClear cell carcinomaClear cell papillary carcinomaCytokeratin 7-positivityDifferential diagnosisVHL gene

Identifiers

PMID31656019
PMCPMC7297853
OpenAlexW2981556246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.